We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Encompass Health (EHC) Proposes 50-Bed Hospital in Florida
Read MoreHide Full Article
Encompass Health Corporation (EHC - Free Report) recently announced plans to construct an inpatient rehabilitation hospital in Daytona Beach, FL. The hospital will house 50 beds and comprise advanced rehabilitation technologies and equipment.
The latest update reflects EHC’s endeavor to expand rehabilitative care across the Atlantic coast of Florida. This, in turn, is likely to aid patients suffering debilitating illnesses and injuries in the Daytona Beach area. A well-versed medical team comprising highly specialized nurses, therapists and physicians will enable Encompass Health to seamlessly serve the region’s residents.
Encompass Health’s one of the most longstanding endeavors is pretty evident from its recent move of footprint expansion throughout Florida. Presently, EHC has 19 inpatient rehabilitation hospitals across the state. The 19th hospital of Florida in St. Petersburg was inaugurated in September 2022.
EHC further plans to penetrate Florida with seven more hospitals, likely to be built in the next few years.
Encompass Health seems to be on a spree to unveil plans to build hospitals across different U.S. states and subsequently, inaugurate the same within a reasonable timeline. Through these hospitals, the ulterior motive of EHC remains to provide specialized rehabilitative care to patients in close proximity to their homes and delve into the underserved parts of the nation grappling with insufficient access to quality care.
Strong demand for high-quality rehabilitation care requires patients to return to their normal daily activities. This provides an impetus to Encompass Health to ramp up its expansion plans.
Additionally, a swift geographical expansion strategy continues to bolster EHC’s nationwide reach and contributes to revenues of its sole operating segment, Inpatient Rehabilitation. Management anticipates net operating revenues within $4,320-$4,350 million for 2022.
Encompass Health’s current count of inpatient rehabilitation hospitals stands at 153, stretching across 36 states and Puerto Rico.
Shares of Encompass Health have lost 12.4% in a year compared with the industry’s decline of 30.8%.
Image Source: Zacks Investment Research
Zacks Rank & Key Picks
Encompass Health currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the Medical space are Medpace Holdings, Inc. (MEDP - Free Report) , Merck & Co., Inc. (MRK - Free Report) and ShockWave Medical, Inc. (SWAV - Free Report) . While Medpace flaunts a Zacks Rank #1 (Strong Buy), Merck and ShockWave Medical carry a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Medpace’s earnings surpassed estimates in each of the last four quarters, the average beat being 22.04%. The Zacks Consensus Estimate for MEDP’s 2022 earnings suggests an improvement of 44.9%, while the same for revenues indicates growth of 27.1% from the respective year-ago reported figures. The consensus mark for MEDP’s 2022 earnings has moved 13.1% north in the past 30 days.
The bottom line of Merck beat estimates in each of the last four quarters, the average surprise being 16.07%. The Zacks Consensus Estimate for MRK’s 2022 earnings suggests an improvement of 22.6%, while the same for revenues implies growth of 17.9% from the respective year-ago reported figures. The consensus mark for MRK’s 2022 earnings has moved 1.1% north in the past 30 days.
ShockWave Medical’s earnings outpaced estimates in each of the trailing four quarters, the average being 146.10%. The Zacks Consensus Estimate for SWAV’s 2022 earnings is pegged at $2.88 per share. The year-ago reported figure was a loss of 26 cents. The consensus mark for SWAV’s 2022 earnings has moved 12.1% north in the past 30 days.
Shares of Medpace, Merck and ShockWave Medical have gained 3%, 28.7% and 29.1%, respectively, in a year.
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Encompass Health (EHC) Proposes 50-Bed Hospital in Florida
Encompass Health Corporation (EHC - Free Report) recently announced plans to construct an inpatient rehabilitation hospital in Daytona Beach, FL. The hospital will house 50 beds and comprise advanced rehabilitation technologies and equipment.
The latest update reflects EHC’s endeavor to expand rehabilitative care across the Atlantic coast of Florida. This, in turn, is likely to aid patients suffering debilitating illnesses and injuries in the Daytona Beach area. A well-versed medical team comprising highly specialized nurses, therapists and physicians will enable Encompass Health to seamlessly serve the region’s residents.
Encompass Health’s one of the most longstanding endeavors is pretty evident from its recent move of footprint expansion throughout Florida. Presently, EHC has 19 inpatient rehabilitation hospitals across the state. The 19th hospital of Florida in St. Petersburg was inaugurated in September 2022.
EHC further plans to penetrate Florida with seven more hospitals, likely to be built in the next few years.
Encompass Health seems to be on a spree to unveil plans to build hospitals across different U.S. states and subsequently, inaugurate the same within a reasonable timeline. Through these hospitals, the ulterior motive of EHC remains to provide specialized rehabilitative care to patients in close proximity to their homes and delve into the underserved parts of the nation grappling with insufficient access to quality care.
Strong demand for high-quality rehabilitation care requires patients to return to their normal daily activities. This provides an impetus to Encompass Health to ramp up its expansion plans.
Additionally, a swift geographical expansion strategy continues to bolster EHC’s nationwide reach and contributes to revenues of its sole operating segment, Inpatient Rehabilitation. Management anticipates net operating revenues within $4,320-$4,350 million for 2022.
Encompass Health’s current count of inpatient rehabilitation hospitals stands at 153, stretching across 36 states and Puerto Rico.
Shares of Encompass Health have lost 12.4% in a year compared with the industry’s decline of 30.8%.
Image Source: Zacks Investment Research
Zacks Rank & Key Picks
Encompass Health currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the Medical space are Medpace Holdings, Inc. (MEDP - Free Report) , Merck & Co., Inc. (MRK - Free Report) and ShockWave Medical, Inc. (SWAV - Free Report) . While Medpace flaunts a Zacks Rank #1 (Strong Buy), Merck and ShockWave Medical carry a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Medpace’s earnings surpassed estimates in each of the last four quarters, the average beat being 22.04%. The Zacks Consensus Estimate for MEDP’s 2022 earnings suggests an improvement of 44.9%, while the same for revenues indicates growth of 27.1% from the respective year-ago reported figures. The consensus mark for MEDP’s 2022 earnings has moved 13.1% north in the past 30 days.
The bottom line of Merck beat estimates in each of the last four quarters, the average surprise being 16.07%. The Zacks Consensus Estimate for MRK’s 2022 earnings suggests an improvement of 22.6%, while the same for revenues implies growth of 17.9% from the respective year-ago reported figures. The consensus mark for MRK’s 2022 earnings has moved 1.1% north in the past 30 days.
ShockWave Medical’s earnings outpaced estimates in each of the trailing four quarters, the average being 146.10%. The Zacks Consensus Estimate for SWAV’s 2022 earnings is pegged at $2.88 per share. The year-ago reported figure was a loss of 26 cents. The consensus mark for SWAV’s 2022 earnings has moved 12.1% north in the past 30 days.
Shares of Medpace, Merck and ShockWave Medical have gained 3%, 28.7% and 29.1%, respectively, in a year.